News Release

<< Back
March 5, 2015 at 4:05 PM EST

AtriCure Announces 2015 Analyst & Investor Meeting

WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for executing on its growth initiatives as well as guest speakers to provide clinical perspective.

Guest speakers:

  • James L. Cox, M.D., cardiothoracic surgeon and developer of the Cox-Maze procedure for the surgical treatment of atrial fibrillation.
  • Jonathan Philpott, M.D., cardiothoracic surgeon and Director of the Sentara Atrial Fibrillation Surgery Program at Sentra Heart Hospital.
  • S. Patrick Whalen, M.D., FHRS, electrophysiologist and Associate Professor of Medicine at Wake Forest Baptist Health.

A live audio webcast and replay of the meeting will be available for 30 days following the meeting on the Investors page of AtriCure’s corporate website at

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 33.5 million people worldwide.

Source: AtriCure, Inc.

AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President and Chief Financial Officer
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678